`a`
Mathematical Biosciences and Engineering (MBE)
 

The role of TNF-$\alpha$ inhibitor in glioma virotherapy: A mathematical model
Pages: 305 - 319, Issue 1, February 2017

doi:10.3934/mbe.2017020      Abstract        References        Full text (1012.0K)           Related Articles

Elzbieta Ratajczyk - Institute of Mathematics, Lodz University of Technology, 90-924 Lodz, Poland (email)
Urszula Ledzewicz - Dept. of Mathematics and Statistics, Southern Illinois University Edwardsville, Edwardsville, Illinois, 62026-1653, United States (email)
Maciej Leszczynski - Institute of Mathematics, Lodz University of Technology, 90-924 Lodz, Poland (email)
Avner Friedman - Mathematical Biosciences Institute & Department of Mathematics, The Ohio State University, Columbus, OH 43210, United States (email)

1 C. Antoni and J. Braun, Side effects of anti-TNF therapy: Current knowledge, Clin Exp Rheumatol, 22 (2002), 152-157.
2 B. Auffinger, A. U. Ahmed and M. S. Lesniak, Oncolytic virotherapy for malignant glioma: Translating laboratory insights into clinical practice, Front. Oncol., 3 (2013), 1-32.
3 E. A. Chiocca, Oncolytic viruses, Nat. Rev. Cancer, 2, 2002, 938-950.
4 L. K. Csatary, G. Gosztonyi, J. Szeberenyi, Z. Fabian, V. Liszka, B. Bodey and C. M. Csatary, MTH-68/H oncolytic viral treatment in human highgrade gliomas, J. Neurooncol, 67 (2004), 83-93.
5 A. Friedman, J. Tian, G. Fulci, E. Chioca and J. Wang, Glioma virotherapy: Effects of innate immune suppression and increased viral replication capacity, Cancer Res., 66 (2006), 2314-2319.
6 G. Fulci, L. Breymann, D. Gianni, K. Kurozomi, S. S. Rhee, J. Yu, B. Kaur, D. N. Louis, R.Weissleder, M. A. Caligiuri and E. A. Chiocca, Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses, PNAS, 103 (2006), 12873-12878.
7 I. Ganly, D. Kirn, G. Eckhardt, G. I. Rodriguez, D. S. Soutar, R. Otto, A. G. Robertson, O. Park, M. L. Gulley, C. Heise, D. D. Von Hoff, S. B. Kaye and S. G. Eckhardt, A phase I study of ONYX-015, an EiBattenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer, Clin. Cancer Res., 6 (2000), 798-806.
8 M. P. Hallsworth, C. P. Soh, S. J. Lane, J. P. Arm and T. H. Lee, Selective enhancement of GM-CSF, TNF-alpha, IL-1 and IL-8 production by monocytes and macrophages of asthmatic subjects, Eur Respir J., 7 (1994), 1096-1102.
9 W. Hao, E. D. Crouser and A. Friedman, Mathematical model of sarcoidosis, PNAS, 111 (2014), 16065-16070.       
10 K. Jacobsen, L. Russel, B. Kaur and A. Friedman, Effects of CCN1 and macrophage content on glioma virotherapy: A mathematical model, Bull Math Biol., 77 (2015), 984-1012.       
11 F. R. Khuri, J. Nemunaitis, I. Ganly, J. Arseneau, I. F. Tannock, L. Romel, M. Gore, J. Ironside, R. H. MacDougall, C. Heise, B. Randley, A. M. Gillenwater, P. Bruse, S. B. Kaye, W. K. Hong and D. H. Kirn, A controlled trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer, Nat. Med., 6 (2000), 879-885.
12 Y. Kim, H. G. Lee, N. Dmitrieva, J. Kim, B. Kaur and A. Friedman, Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: A mathematical model, PLOS ONE, 9 (2014), e102499.
13 R. M. Lorence, A. L. Pecora, P. P. Major, S. J. Hotte, S. A. Laurie, M. S. Roberts, W. S. Groene and M. K. Bamat, Overview of phase I studies of intravenous administration of PV701, an oncolytic virus, Curr. Opin. Mol. Ther., 5 (2003), 618-624.
14 J. M. Markert, Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial, Gene. Ther., 7 (2000), 867-874.
15 W. H. Meisen, E. S. Wohleb, A. C. Jaime-Ramirez, C. Bolyard, J. Y. Yoo, L. Russel, J. Hardcastle, S. Dubin, K. Muili, J. Yu, M. Callgiuri, J. Godbout and B. Kaur, The impact of macrophage- and microglia- secreted TNF-$\alpha$ on oncolitic hsv-1 therapy in the glioblastoma tumor microenvironment, Clin Cancer Res., 21 (2015), 3274-3285.
16 T. Mineta, S. Rabkin, T. Yazaki, W. Hunter and R. Martuza, Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas, Nat. Med., 1 (1995), 938-943.
17 J. C. Oliver, L. A. Bland, C. W. Oettinger, M. J. Arduino, S. K. McAllister, S. M. Aguero and M. S. Favero, Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge, Lymphokine Cytokine Res., 12 (1993), 115-120.
18 R. Rodriguez, E. R. Schuur, H. Y. Lim, G. A. Henderson, J. W. Simons and D. R. Henderson, Prostate attenuated replication competent daenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific anti-positive prostate cancer cells, Cancer Res., 57 (2000), 2559-2563.
19 H. Schättler and U. Ledzewicz, Optimal Control for Mathematical Models of Cancer Therapies, Springer Publishing Co., New York, USA, 2015.       
20 G. Wollmann, K. Ozduman and A. N. van den Pol, Oncolytic virus therapy for glioblastoma multiforme: Concepts and candidates, Cancer J., 18 (2012), 69-81.
21 J. T. Wu, H. M. Byrne, D. H. Kirn and L. M. Wein, Modeling and analysis of a virus that replicates selectively in tumor cells, Bull. Math. Biol., 63 (2001), 731-768.
22 J. T. Wu, D. H. Kirn and L. M. Wein, Analysis of a three-way race between tumor growth, a replication-competent virus and an immune response, Bull. Math. Biol., 66 (2004), 605-625.       

Go to top